493. Deputy John Connolly asked the Minister for Health further to Parliamentary Question No. 1964 of 18 March 2026, relating to omaveloxolone skyclarys®, whether any interim arrangements are available or under consideration whereby, in circumstances where a family is willing to travel abroad, a patient could be facilitated in accessing this treatment while the drug remains under assessment by the HSE; whether the Na…
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
540. Deputy Ken O'Flynn asked the Minister for Health to clarify the current operational status of any early access or compassionate access schemes for rare disease medicines; and to confirm whether any such schemes are currently available to patients in Ireland. [33756/26]
828. Deputy Colm Burke asked the Minister for Health the plans to tackle the promotion and sale of counterfeit obesity medicines online and offline which are in breach of the law, endanger public health and can contribute to organised crime. [32947/26]
829. Deputy Pádraig O'Sullivan asked the Minister for Health the steps her Department is taking to ensure continuity of medication management supports for adults and children with disabilities and cognitive impairment, particularly in respect of the safe use of monitored dosage systems where these are clinically indicated; and if she will make a statement on the matter. [33043/26]
830. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has carried out, or commissioned, any assessment of the impact on persons with disabilities of the requirement to privately fund pharmacist-prepared blister packs and monitored dosage systems where such supports are recommended on safety grounds; and if she will make a statement on the matter. [33044/26]
832. Deputy Rose Conway-Walsh asked the Minister for Health whether the drug sotatercept, approved for the treatment of pulmonary hypertension in other jurisdictions, will be made available to patients in Ireland; and if she will make a statement on the matter. [31813/26]
834. Deputy Louis O'Hara asked the Minister for Health if people living with type 2 diabetes could be made eligible for free dexcom continuous glucose monitoring (CGM) devices under the long-term illness scheme; and if she will make a statement on the matter. [31851/26]
838. Deputy Albert Dolan asked the Minister for Health whether she is satisfied that current reimbursement timelines for orphan medicines align with the commitments on timely and equitable access set out in the National Rare Disease Strategy 2025–2030; the measures that are being taken to address delays in cases where EMA-approved treatments, including those for Friedreich’s ataxia, remain unavailable to patients in …
841. Deputy Ciarán Ahern asked the Minister for Health if consideration is being given to funding the Alzheimer’s drug lecanemab; and if she will make a statement on the matter. [31918/26]
859. Deputy Peter 'Chap' Cleere asked the Minister for Health if she will expedite and accept the appeal of a person (details supplied); and if she will make a statement on the matter. [31983/26]
871. Deputy Barry Ward asked the Minister for Health if her attention has been drawn to delays in the sign off of fertility treatment by the Health Products Regulatory Authority (details supplied); the actions she will take to address this matter; and if she will make a statement on the matter. [32100/26]
872. Deputy Barry Ward asked the Minister for Health if her attention has been drawn to significant delays in the sign off of fertility treatment for a family (details supplied); the actions she will take to ensure they are supported; and if she will make a statement on the matter. [32101/26]
895. Deputy Colm Burke asked the Minister for Health to clarify the 5 January 2026 memo from the HSE Codeine Working Group instructing that low dose codeine-containing products should not be stocked routinely in clinical areas in any HSE or HSE-funded service, and that they be removed from clinical stock by 5 June 2026; if she will confirm whether this reflects official Department of Health or HSE policy; and if she …
896. Deputy Colm Burke asked the Minister for Health to clarify claims in the 5 January 2026 HSE memo that low-dose codeine combination products are no more effective than paracetamol or ibuprofen alone; to identify the evidence base for this; to confirm current policy on managing chronic pain; and if she will make a statement on the matter. [32234/26]
897. Deputy Colm Burke asked the Minister for Health if she will provide details of the HPRA’s engagement with patient groups and stakeholders during its ongoing review of over-the-counter codeine medicines which commenced in November 2022, including which organisations were consulted and the nature of that engagement; and if she will make a statement on the matter. [32235/26]
898. Deputy Colm Burke asked the Minister for Health if she is satisfied that the HPRA review process on over-the-counter codeine medicines meets the required standards of transparency, proportionality and scientific rigour; and if she will make a statement on the matter. [32236/26]
899. Deputy Colm Burke asked the Minister for Health to clarify the basis for the 5 January 2026 memo of the HSE codeine working group on low-dose codeine stating that low dose paracetamol ibuprofen are no more effective than paracetamol or ibuprofen alone for the management of pain; to instruct that low-dose codeine products should not be stocked routinely in clinical areas in any HSE or HSE-funded service, to remov…
914. Deputy Johnny Guirke asked the Minister for Health in relation to the free contraception scheme, the reason commonly used contraceptive medication such as elvina are still excluded; the steps being taken to ensure this scheme becomes genuinely inclusive of all available prescribed contraceptive pills; the processes in place to review and reconsider whether each type of pill is included for funding; and if she wi…
942. Deputy Ken O'Flynn asked the Minister for Health whether national clinical guidelines are in place governing access to pharmacological treatments for obesity within the public health service; if so, to provide details of those guidelines and the eligibility criteria applied; and if she will make a statement on the matter. [32352/26]
944. Deputy Ken O'Flynn asked the Minister for Health whether any procurement or reimbursement decisions are under consideration in relation to new pharmacological treatments for obesity; if so, to outline the current status of those considerations and the decision-making framework applied; and if she will make a statement on the matter. [32354/26]
1121. Deputy Ken O'Flynn asked the Minister for Health whether any patients in the State currently have access to omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia through compassionate use, named patient access, hospital-level approval, exceptional funding, or any other interim access mechanism pending a final HSE reimbursement decision; and if she will make a statement on the matter. [32771/26]
1122. Deputy Ken O'Flynn asked the Minister for Health the number of patients in the State known to the HSE or the Department of Health who are clinically eligible for treatment with omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia; and if this number has informed any budget impact assessment. [32772/26]
1123. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a target timeline for completing reimbursement decisions in respect of orphan medicines or medicines for progressive rare diseases; and if no such target exists, whether one is under consideration. [32773/26]
1124. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has any escalation process where a reimbursement application concerns a progressive neurological condition in which delay may lead to irreversible deterioration. [32774/26]
1125. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered international reimbursement or access decisions in respect of omaveloxolone, marketed as Skyclarys, including decisions in France, Italy, Germany or other comparable European countries, as part of the Irish reimbursement process. [32775/26]